Superworth

Biotech stocks with the fastest revenue growth

Revenue over the last twelve months against the twelve months before. As of .

Ranked
36
of 146 biotech stocks we cover
Median
+28.5%
Highest
+292.2%
AUTL
Range
−61.6% to +292.2%
median +28.5%
−61.6%+292.2%
#CompanyRevenue growthNet marginPrice to salesMarket cap
1AUTLAutolus Therapeutics+292.2%n/m3.2×$378M
2IBRXImmunityBio+192.9%n/m50.8×$8.4B
3INSMInsmed+185.8%−76.9%20.8×$23.7B
4BEAMBeam Therapeutics+163.3%−54.7%17.1×$2.7B
5KYMRKymera Therapeutics+134.8%n/m101×$10.6B
6TARSTarsus Pharmaceuticals+105.2%−7.7%5.3×$3.2B
7ALNYAlnylam Pharmaceuticals+95.1%16.8%4.4×$21.2B
8FENCFennec Pharmaceuticals+77.8%−5.5%6.2×$369.6M
9BCRXBiocryst Pharmaceuticals+68.7%−40.9%2.2×$2.1B
10CHRSCoherus Oncology+61.0%n/m2.3×$115.8M
11RXRXRecursion Pharmaceuticals+56.2%n/m37.4×$2.1B
12ADPTAdaptive Biotechnologies+50.1%−20.7%13.0×$4B
13HALOHalozyme Therapeutics+41.2%24.9%8.8×$14.6B
14IOVAIovance Biotherapeutics+34.5%−89.1%11.2×$3.6B
15NBIXNeurocrine Biosciences+34.4%20.9%4.4×$14.8B
16ONCBeOne Medicines+34.3%10.7%6.6×$40.2B
17AGENAgenus+30.5%69.3%2.2×$294M
18PLXProtalix BioTherapeutics+30.1%23.5%2.6×$206.3M
19INCYIncyte+26.9%27.7%4.2×$24.3B
20IVVDInvivyd+26.3%n/m2.9×$171.5M
21VCELVericel+23.0%7.9%6.8×$2.1B
22KRYSKrystal Biotech+22.6%54.8%19.9×$8.8B
23IMCRImmunocore+21.0%−4.2%3.6×$1.5B
24TWSTTwist Bioscience+19.2%−31.7%18.7×$8.1B
25RGENRepligen+16.5%5.3%12.4×$9.8B
26RGNXREGENXBIO+12.0%n/m2.7×$472.7M
27VRTXVertex Pharmaceuticals+10.5%35.0%10.9×$137.1B
28REGNRegeneron Pharmaceuticals+9.3%27.9%6.4×$100B
29EXELExelixis+9.2%35.3%7.1×$17.4B
30ADMAAdma Biologics+8.0%33.0%4.8×$2.5B
31CSBRChampions Oncology+6.7%−1.8%1.1×$66.9M
32UTHRUnited Therapeutics+2.5%41.6%8.2×$25.9B
33TECHBIO-TECHNE−0.4%15.0%9.4×$11.4B
34MRNAModerna−27.6%n/m41.3×$92.1B
35DNAGinkgo Bioworks−46.8%n/m5.9×$663.3M
36NVAXNovavax−61.6%−59.9%3.8×$1.6B

Not ranked: 32 with not a meaningful number, 32 with under $50M of revenue, 16 with a quarter missing, 6 with growth from a base too small to compare. 24 companies whose data behind this number has a caveat are left out until it is checked.

A ranking of numbers, not a recommendation. A low multiple can be a bargain or a business in trouble: open the company to see which.

Revenue growth for other groups

Other rankings of biotech stocks

The group